Extension Study for Patients Who Completed GENA-05 (NuProtect)- to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Simoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacodynamics; Registrational
- Sponsors Octapharma
- 14 Oct 2015 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2018, according to ClinicalTrials.gov record.
- 19 May 2014 Planned end date changed from 1 Jan 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov.
- 19 May 2014 Trial status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.